glp-1 incretin Reporter Cells | Bioassay Isomaltulose enhances incretin GLP-1 secretion

And what can you realistically expect from treatment

Preliminary results from the SURPASS-J-mono study in Japanese patients with T2D who were either therapy nave or on an antidiabetic monotherapy showed a head-to-head comparison of a tirzepatide treatment compared to therapy with the GLP-1RA dulaglutide at a dose of 0.75 mg (54, 76)

Needless to say, theyre not cheap

Clinical data consistently shows that lean mass accounts for approximately 25 to 40 percent of total weight lost during GLP-1 receptor agonist therapy

These are all partially correct, but none capture the full picture

Headaches that persist beyond the first 23 weeks or worsen over time warrant provider re-evaluation